PSGL1 Human ELISA Kit (ab119555)
- Product namePSGL1 Human ELISA Kit
- Detection methodColorimetric
Intra-assay Sample n Mean SD CV% Overall 3.2%
- Tests1 x 96 test
- Sample typeCell culture supernatant, Serum
- Assay typeSandwich (quantitative)
- Sensitivity1 U/ml
- Range1.6 U/ml - 50 U/ml
Sample specific recovery Sample type Average % Range Serum 94 83% - 104%
- Assay durationMultiple steps standard assay
- Species reactivityReacts with: Human
- Product overview
Abcam’s PSGL1 Human in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for accurate quantitative measurement of Human PSGL1 concentrations in cell culture supernatant and serum.
This assay employs a monoclonal antibody for Human PSGL1 coated on a 96-well plate. Standards and samples are pipetted into the wells and PSGL1 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated monoclonal anti- Human PSGL1 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated Streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of PSGL1 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
- Tested applicationsSandwich ELISA more details
- Storage instructionsStore at +4°C. Please refer to protocols.
Components 1 x 96 tests 20X Assay Buffer Concentrate 1 x 5ml 20X Wash Buffer Concentrate 1 x 50ml Adhesive Films 4 units Biotin-Conjugate anti-human PSGL1 monoclonal antibody 1 x 100µl Blue-Dye 1 x 400µl Green-Dye 1 x 400µl Human PSGL1 Standard lyophilized (100 U/ml upon reconstitution) 2 vials Microplate coated with monoclonal antibody to Human PSGL1 (12 x 8 wells) 1 unit Red-Dye 1 x 400µl Sample Diluent 1 x 50ml Stop Solution (1M Phosphoric acid) 1 x 15ml Streptavidin-HRP 1 x 150µl TMB Substrate Solution 1 x 15ml
- Research Areas
- FunctionA SLe(x)-type glycan, which through high affinity, calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation. PSGL1 is critical for the initial leukocyte capture.
- Tissue specificityExpressed on neutrophils, monocytes and most lymphocytes.
modificationsDisplays complex, core-2, sialylated and fucosylated O-linked oligosaccharides, at least some of which appear to contain poly-N-acetyllactosamine with varying degrees of substitution. Mainly disialylated or neutral forms of the core-2 tetrasaccharide, Galbeta1-->4GlcNAcbeta1-->6(Galbeta1-->3)GalNAcOH. The GlcN:GalN ratio is approximately 2:1 and the Man:Fuc ratio 3:5. Contains about 14% fucose with alpha-1,3 linkage present in two forms: One species is a disialylated, monofucosylated glycan, and the other, a monosialylated, trifucosylated glycan with a polylactosamine backbone. The fucosylated forms carry the Lewis antigen and are important for interaction with selectins and for functioning in leukocyte rolling. The modification containing the sialyl Lewis X glycan is on Thr-57. No sulfated O-glycans. Some N-glycosylation.
Sulfation, in conjunction with the SLe(x)-containing glycan, is necessary for P- and L-selectin binding. High affinity P-selectin binding has a preferred requirement for the isomer sulfated on both Tyr-48 and Tyr-51, whereas L-selectin binding requires predominantly sulfation on Tyr-51 with sulfation on Tyr-48 playing only a minor role. These sulfations play an important role in L- and P-selectin-mediated neutrophil recruitment, and leukocyte rolling.
- Cellular localizationMembrane.
- CD162 antigen
- Cutaneous lymphocyte associated associated antigen
- P-selectin glycoprotein ligand 1
- PSGL 1
- Selectin P ligand
Our Abpromise guarantee covers the use of ab119555 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
References for PSGL1 Human ELISA Kit (ab119555)
ab119555 has not yet been referenced specifically in any publications.